MyoKardia, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases. The firm focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It offers MYK-46, an orally-administered small molecule designed to reduce excessive cardiac muscle contractility to hypertrophic cardiomyopathy. The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in San Francisco, CA.